Search

Your search keyword '"Burger, J.P.W."' showing total 5 results
Start Over Author "Burger, J.P.W."
5 results on '"Burger, J.P.W."'

1. Adherence to guideline recommendations for Barrett's esophagus (BE) surveillance endoscopies: Effects of dedicated BE endoscopy lists

Author

Beaufort, I.N., additional, Milne, A.N., additional, Alderlieste, Y.A., additional, Baars, J.E., additional, Bos, P.R., additional, Burger, J.P.W., additional, van Heel, N.C.M., additional, Ledeboer, M., additional, Lieverse, R.J., additional, van de Meeberg, P.C., additional, Meeuse, J.J., additional, Naber, A.H.J., additional, Pullens, H.J.M., additional, Scheffer, R.C.H., additional, Sikkema, M., additional, Verbeek, R.E., additional, Verhagen, M.A.M.T., additional, van de Vrie, W., additional, Willems, M., additional, and Weusten, B.L.A.M., additional

Published
2023
Full Text
View/download PDF

2. Quality of life in coeliac disease

Author

Drenth, J.P.H., Wahab, P.J., Burger, J.P.W., Drenth, J.P.H., Wahab, P.J., and Burger, J.P.W.

Abstract

Radboud University, 11 april 2023, Promotor : Drenth, J.P.H. Co-promotor : Wahab, P.J., Contains fulltext : 291359.pdf (Publisher’s version ) (Closed access)

Published
2023

3. Quality of life in coeliac disease.

Author

Burger, J.P.W. and Burger, J.P.W.

Subjects
Radboudumc 11: Renal disorders., Radboudumc 11: Renal disorders Gastroenterology.
Published
2023

4. Dose-Escalating (50-500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial

Author

Burger, J.P.W., Lochem, E.G. van, Roovers, E.A., Drenth, J.P.H., Wahab, P.J., Burger, J.P.W., Lochem, E.G. van, Roovers, E.A., Drenth, J.P.H., and Wahab, P.J.

Abstract

Contains fulltext : 252147.pdf (Publisher’s version ) (Open Access), BACKGROUND: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. METHODS: We performed a prospective double-blinded placebo-controlled study, including adults with coeliac disease adhering to a strictly gluten-free diet. Patients were administered gluten in test-cycles of ascending doses of 50, 100, 200, and 500 mg alternated with placebo. Urine portions from 2, 5-17 h after the ingestion were collected and analyzed for GIP using the iVYCHECK-GIP-Urine rapid lateral flow test. Patients completed a diary mapping symptoms (nausea, bloating, diarrhea, abdominal pain, and lower level of energy). RESULTS: We enrolled 15 patients and 7 received all 4 cycles with increasing gluten dosing. GIP was detected from urine in 47% of the patients receiving 50 mg gluten and in 86% with 500 mg gluten. We detected GIP in 20-50% of urine samples after placebo. There was no correlation between symptoms, gluten administration and/or GIP in urine. CONCLUSIONS: Gluten intake, even with a dose as low as 50 mg, leads to detectable urinary GIP concentrations. There is no correlation of coeliac disease ascribed symptoms with detection of urinary GIP.

Published
2022

5. Accuracy of upper endoscopies with random biopsies to identify patients with gastric premalignant lesions who can safely be exempt from surveillance

Author

Mommersteeg, M.C. (Michiel C.), Nieuwenburg, S.A.V. (Stella), Hollander, W. (Wouter) den, Holster, L. (Lisanne), Hoed, C.M. (Caroline) den, Capelle, L.G. (Lisette), Tang, T.J. (Tjon J.), Anten, M.-P.G.F. (Marie-Paule G.F.), Prytz-Berset, I. (Ingrid), Witteman, E.M. (Ellen M.), Borg, F. (Frank) ter, Burger, J.P.W. (Jordy P. W.), Doukas, M. (Michael), Bruno, M.J. (Marco J.), Peppelenbosch, M.P. (Maikel), Fuhler, G.M. (Gwenny), Kuipers, E.J. (Ernst J.), Spaander, M.C.W. (Manon), Mommersteeg, M.C. (Michiel C.), Nieuwenburg, S.A.V. (Stella), Hollander, W. (Wouter) den, Holster, L. (Lisanne), Hoed, C.M. (Caroline) den, Capelle, L.G. (Lisette), Tang, T.J. (Tjon J.), Anten, M.-P.G.F. (Marie-Paule G.F.), Prytz-Berset, I. (Ingrid), Witteman, E.M. (Ellen M.), Borg, F. (Frank) ter, Burger, J.P.W. (Jordy P. W.), Doukas, M. (Michael), Bruno, M.J. (Marco J.), Peppelenbosch, M.P. (Maikel), Fuhler, G.M. (Gwenny), Kuipers, E.J. (Ernst J.), and Spaander, M.C.W. (Manon)

Abstract

Introduction: Guidelines recommend endoscopy with biopsies to stratify patients with gastric premalignant lesions (GPL) to high and low progression risk. High-risk patients are recommended to undergo surveillance. We aimed to assess the accuracy of guideline recommendations to identify low-risk patients, who can safely be discharged from surveillance. Methods: This study includes patients with GPL. Patients underwent at least two endoscopies with an interval of 1–6 years. Patients were defined ‘low risk’ if they fulfilled requirements for discharge, and ‘high risk’ if they fulfilled requirements for surveillance, according to European guidelines (MAPS-2012, updated MAPS-2019, BSG). Patients defined ‘low risk’ with progression of disease during follow-up (FU) were considered ‘misclassified’ as low risk. Results: 334 patients (median age 60 years IQR11; 48.7% mal

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results